OBJECTIVES - The objective of the study was to provide utilization data in Germany for the ADHD stimulant medication lisdexamfetamine dimesylate (LDX) in the first six months following its launch in June 2013. METHODS - This drug utilization study (DUS) analysed a longitudinal electronic medical record database (IMS Disease Analyzer - Germany), and was part of a larger DUS providing data for 8 European countries for up to 5 years. The study included records of all patients who had been prescribed LDX from June 2013 to December 2013 in the paediatrician panel (PP) or neurologist/psychiatrist panel (NPP) of the German database. RESULTS - The analysis included 123 patients (348 prescriptions) from the PP and 296 patients (710 prescriptions) from the NPP. In both panels, 91% of patients had a documented diagnosis of ADHD. When initiated on LDX treatment, most patients (PP, 98%; NPP, 91%) were between 6 and 18 years of age; up to 1% of patients in both panels were below 6 years of age and 2% and 8% of patients in the PP and NPP, respectively, were above 18 years of age.  The majority of patients in both panels were male (PP, 77%; NPP, 79%). The average prescribed daily dose of LDX was within the recommended range (30–70 mg) for all patients in the NPP and for 98.4% in the PP, with a mean daily dose across patients of 42 mg in both panels. CONCLUSIONS - The findings of this analysis of electronic medical records indicate that, during the first six months after launch, LDX was mainly prescribed in Germany within the EMA-approved Summary of Product Characteristics (SmPC) with regard to the indicated patients, age group and dose regimen.